Delta: A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals

Lancet

Volumn 348, Issue 9023, 1996, Pages 283-291

  Darbyshire, J H ^a   Aboulker, J P ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DIDANOSINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MOUTH ULCER; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

EID: 0030567824     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)05387-1     Document Type: Article

References (24)

1. Fischl MA, Richman DD, Grieco MH, et al, and the AZT Collaborative Working Group. The efficacy and azidothymidine (AZT) in the treatment of participants with AIDS and AIDS-related complex: a double-blind, placebo-cont rolled trial. N Engl J Med 1987; 317: 185-91.
2. Fischl MA, Richmond DD, Causey DM, et al. Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. JAMA 1989; 262: 2405-10.
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322(14): 941-49.
4. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection. JAMA 1994; 272: 437-42.
5. Cooper DA, Gatell JM, Kroon Set al. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group. N Engl J Med. 329(5):1993;297-303.
6. Volberding PA, Lagakos SW, Grimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell count of 500 or more per cubic millimetre. N Engl J Med 1995; 333: 401-07.
7. Concorde Coordinating Committee. Concorde: MRC/ANRS randomised double-blind controlled trial in immediate and deferred zidovudine in symptom-free HIV infection. Lancet 1994; 343: 871-81.
8. Larder B, Darby G, Richman DD. HIV with reduced sensitivity in zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-34.
9. Richman DD, Grimes JM, Lagakos SW. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS 1990; 3: 743-46.
10. Yarchoan R, Lietzau JA, Nguyen BYet al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis. 169(1):1994;9-17.
11. Meng TC, Fischl MA, Boota AMet al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med. 116(1):1992;13-20.
12. Revision of the CDC surveillance case definition for Acquired Immunodeficiency Syndrome. MMWR 1987; 36 (supp 1S): 3S-13S.
13. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992; 41 (HR-17): 1-19.
14. Pocock SJ. Clinical trials: a practical approach. Chichester: Wiley, 1988.
15. Peto R, Pike MC, Armitage Pet al. Design and analysis of randomised clinical trials requiring prolonged observation of each participant, II: analysis and examples. Br J Cancer. 35:1977;1-39.
16. Classification system for human T-lymphotrophic virus type III/lymphadenopathy-associated virus infections. MMWR 1986; 35 (20): 334-39.
17. Neaton JD, Wentworth DN. Methods of studying interventions. Considerations in choice of a clinical endpoint for AIDS clinical trials. Stat Med 1994; 13: 2107-25.
18. Cox DR Regression models and life tables. J R Statist Soc B. 34:1972;187-220.
19. 3. EACS 5th European Conference of Clinical Aspects and Treatment of HIV infection. September 1995. Copenhagen.
20. 3. 3rd Conference on Retroviruses and Opportunistic Infections. Washington Jan 28-Feb 1, 1996; Abst LB4: p 161.
21. Kahn JO, Lagakos SW, Richman DD, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. N Engl J Med 1992; 327: 581-87.
22. Alpha Coordinating Committee. European/Australian randomised double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. AIDS 1996; 10: 867-80.
23. Abrams DI, Goldman AI, Launer C, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med 1994; 330: 657-62.
24. 3rd Conference on Retroviruses and Opportunistic Infections. Washington Jan 28-Feb 1, 1996.